Altimmune Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Vipin Garg

Algemeen directeur

US$5.5m

Totale compensatie

Percentage CEO-salaris	11.3%
Dienstverband CEO	6yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	5.3yrs
Gemiddelde ambtstermijn bestuur	5.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Vipin Garg's beloning veranderd ten opzichte van Altimmune's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$101m
Mar 31 2024	n/a	n/a	-US$93m
Dec 31 2023	US$5m	US$620k	-US$88m
Sep 30 2023	n/a	n/a	-US$78m
Jun 30 2023	n/a	n/a	-US$81m
Mar 31 2023	n/a	n/a	-US$85m
Dec 31 2022	US$3m	US$580k	-US$85m
Sep 30 2022	n/a	n/a	-US$87m
Jun 30 2022	n/a	n/a	-US$97m
Mar 31 2022	n/a	n/a	-US$102m
Dec 31 2021	US$3m	US$566k	-US$97m
Sep 30 2021	n/a	n/a	-US$84m
Jun 30 2021	n/a	n/a	-US$68m
Mar 31 2021	n/a	n/a	-US$60m
Dec 31 2020	US$1m	US$514k	-US$49m
Sep 30 2020	n/a	n/a	-US$43m
Jun 30 2020	n/a	n/a	-US$36m
Mar 31 2020	n/a	n/a	-US$22m
Dec 31 2019	US$815k	US$500k	-US$21m
Sep 30 2019	n/a	n/a	-US$42m
Jun 30 2019	n/a	n/a	-US$34m
Mar 31 2019	n/a	n/a	-US$40m
Dec 31 2018	US$2m	US$44k	-US$42m

Compensatie versus markt: De totale vergoeding ($USD 5.48M ) Vipin } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 1.02M ).

Compensatie versus inkomsten: De vergoeding van Vipin is gestegen terwijl het bedrijf verliesgevend is.

CEO

Vipin Garg (66 yo)

6yrs

Tenure

US$5,482,089

Compensatie

Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Vipin Garg	President	6yrs	US$5.48m	0.41% $ 2.1m
Matthew Harris	Chief Medical Officer	5.3yrs	US$2.24m	0.078% $ 402.9k
Raymond Jordt	Chief Business Officer	1.8yrs	US$2.94m	0.021% $ 107.2k
Andrew Shutterly	Acting CFO	1.8yrs	geen gegevens	0.016% $ 83.1k
Bertrand Georges	Chief Technology Officer	7.5yrs	geen gegevens	geen gegevens
M. Roberts	Chief Scientific Officer	11.9yrs	US$1.41m	0.061% $ 316.7k
Tony Blandin	Vice President of Quality & Compliance Management	2.8yrs	geen gegevens	geen gegevens

5.3yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0A4C is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Vipin Garg	President	6yrs	US$5.48m	0.41% $ 2.1m
Mitchel Sayare	Independent Chairman	14.6yrs	US$119.68k	0.037% $ 192.7k
John Gill	Independent Director	20.3yrs	US$103.68k	0.0039% $ 20.3k
Philip Hodges	Independent Director	7.5yrs	US$115.68k	0.012% $ 63.8k
Klaus Schafer	Independent Director	7.5yrs	US$104.68k	0.013% $ 67.1k
Catherine Sohn	Independent Director	1.7yrs	US$273.47k	0% $ 0
Wayne Pisano	Independent Director	6.3yrs	US$108.68k	0.012% $ 62.1k
Caroline Apovian	Member of Obesity Scientific Advisory Board	2.3yrs	geen gegevens	geen gegevens
Diane Jorkasky	Independent Director	4.5yrs	US$95.68k	0% $ 0
Rohit Loomba	Member of Mash Scientific Advisory Board	2.3yrs	geen gegevens	geen gegevens
Mazen Noureddin	Member of Mash Scientific Advisory Board	2.3yrs	geen gegevens	geen gegevens
Naga Chalasani	Member of Mash Scientific Advisory Board	2.3yrs	geen gegevens	geen gegevens

5.3yrs

Gemiddelde duur

71.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0A4C wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).

Altimmune Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

High number of new directors

High number of new directors

Altimmune, Inc., Annual General Meeting, Sep 26, 2024

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

Altimmune, Inc., Annual General Meeting, Sep 28, 2023

Altimmune, Inc. Appoints Raymond Jordt as Chief Business Officer

Recent updates

Altimmune, Inc. to Report Q3, 2024 Results on Nov 12, 2024

High number of new directors

High number of new directors

Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (Mash)

Altimmune, Inc., Annual General Meeting, Sep 26, 2024

New major risk - Revenue and earnings growth

First half 2024 earnings released: US$0.69 loss per share (vs US$0.72 loss in 1H 2023)

New major risk - Revenue and earnings growth

Altimmune, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Altimmune, Inc. Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association’s 84th Scientific Sessions

Altimmune, Inc. Presents Data at EASL International Liver Congress™? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)

Pomerantz LLP Announces Filing of Class Action Against Altimmune, Inc. and Certain Officers

Altimmune, Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings released: US$1.66 loss per share (vs US$1.81 loss in FY 2022)

New major risk - Revenue and earnings growth

Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023

Altimmune, Inc. to Report Q4, 2023 Results on Mar 27, 2024

New major risk - Share price stability

Altimmune, Inc. Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

Third quarter 2023 earnings released: US$0.39 loss per share (vs US$0.48 loss in 3Q 2022)

Altimmune, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Altimmune, Inc. Grants Fast Track Designation by FDA for Pemvidutide for the Treatment of Non Alcoholic Steatohepatitis (Nash)

Altimmune, Inc., Annual General Meeting, Sep 28, 2023

Altimmune, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Altimmune, Inc. Announces Initiation of Phase 2b Impact Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Al Alcoholic Steatohepatitis

Altimmune, Inc. to Report Q1, 2023 Results on May 11, 2023

Altimmune, Inc. Appoints Raymond Jordt as Chief Business Officer

Altimmune, Inc. Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease

Third quarter 2022 earnings released: US$0.48 loss per share (vs US$0.81 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.48 loss per share (vs US$0.81 loss in 3Q 2021)

Altimmune, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

Altimmune, Inc. Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

Altimmune, Inc., Annual General Meeting, Sep 29, 2022

Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.60 loss in 2Q 2021)

Altimmune, Inc. to Report Q2, 2022 Results on Aug 11, 2022

First quarter 2022 earnings released: US$0.44 loss per share (vs US$0.38 loss in 1Q 2021)

Altimmune, Inc. to Report Q1, 2022 Results on May 12, 2022

Insufficient new directors

Insufficient new directors

Altimmune Announces Initiation of 48-Week Phase 2 Momentum Trial of Pemvidutide in Obesity

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity

Insufficient new directors

Insufficient new directors

Third quarter 2021 earnings released: US$0.81 loss per share (vs US$0.54 loss in 3Q 2020)

Altimmune Announces Positive Results from 12-Week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers

Altimmune, Inc. Reports an Impairment on Construction-In-Progress for the Three Months Ended June 30, 2021

Second quarter 2021 earnings released: US$0.60 loss per share (vs US$0.94 loss in 2Q 2020)

Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial

Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers

Forecast breakeven pushed back to 2024

Altimmune, Inc. Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID™

First quarter 2021 earnings released: US$0.38 loss per share (vs US$0.26 loss in 1Q 2020)

Forecast breakeven pushed back to 2025

Altimmune Announces New Preclinical Data for AdCOVID™ Demonstrating Sterilizing Immunity After a Single Intranasal Dose

Altimmune, Inc. Announces Additional Preclinical Data for Its Single Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID

Full year 2020 earnings released: US$1.91 loss per share (vs US$1.60 loss in FY 2019)

Revenue beats expectations

Altimmune, Inc. Commences Enrollment in Phase 1 Clinical Trial of AdCOVID- A Needle-Free, Single-Dose Intranasal Covid-19 Vaccine Candidate

Altimmune, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021

Altimmune, Inc. Announces FDA Clearance of AdCOVID™ IND Application

Altimmune, Inc. Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B

Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial

Altimmune Announces Submission of Investigational New Drug Application To the U.S. Food and Drug Administration to Commence A Phase 1 Clinical Study of Its Single-Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID